Less invasive diagnostics for identification and monitoring of cancer associated mutations in blood

Less invasive diagnostics for identification and monitoring of cancer associated mutations in blood - Liquid biopsy: monitoring cancer-genetics in the blood

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000012810

Enrollment

600

Registered

2014-01-10

Start date

2013-10-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients suffering from tumors such as colorectal, lung and pancreatic cancer and precancerous disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with benign and malignant tumor and healthy volunteers Patients with written informed consent

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Quantitative detection and monitoring of genetic mutations in tumor-associated genes, such as oncogenic KRAS, in circulating plasma DNA.	—

Secondary

Measure	Time frame
Comparison of the oncogenetic mutations in plasma DNA with those in corresponding tumor tissue DNA.	—

Countries

Japan

Contacts

Public ContactYusuke Mizukami

Center for Clinical and Biomedical Research, Sapporo Higashi Tokushukai Hospital Division of Cancer Research

ymizu_ccbr@tohtoku.jp011-722-1110

Outcome results